Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patientsAlejandro Contreras, MF Rimawi, Sabrina Herrera et al.|Cancer Research|2013Cited by 18
P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer.Livia Malorni, Rachel Schiff, CJ Creighton et al.|Cancer Research|2011Cited by 1